CoChat

Dual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal Cancers

Open access
Temraz, Sally, Mukherji, Deborah, Shamseddine, Ali · 2015 · International Journal of Molecular Sciences

The DOI matches its Crossref record; 54 of the 55 references it cites were found in a registry or an index.

Abstract

Colorectal cancer (CRC) is a heterogeneous disease with multiple underlying causative genetic mutations. Genetic mutations in the phosphatidylinositol-3 kinase (PI3K) and the mitogen activated protein kinase (MAPK) pathways are frequently implicated in CRC. Targeting the downstream substrate MEK in these mutated tumors stands out as a potential target in CRC. Several selective inhibitors of MEK have entered clinical trial evaluation; however, clinical activity with single MEK inhibitors has been rarely observed and acquired resistance seems to be inevitable. Amplification of the driving oncogene KRAS(13D), which increases signaling through the ERK1/2 pathway, upregulation of the noncanonical wingless/calcium signaling pathway (Wnt), and coexisting PIK3CA mutations have all been implicated with resistance against MEK inhibitor therapy in KRAS mutated CRC. The Wnt pathway and amplification of the oncogene have also been associated with resistance to MEK inhibitors in CRCs harboring BRAF mutations. Thus, dual targeted inhibition of MEK and PI3K pathway effectors (mTOR, PI3K, AKT, IGF-1R or PI3K/mTOR inhibitors) presents a potential strategy to overcome resistance to MEK inhibitor therapy. Many clinical trials are underway to evaluate multiple combinations of these pathway inhibitors in solid tumors.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/ijms160922976

Cites

54 of 54 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Cross talk between MAPK, PI3K and Wnt pathway in CRC. Upon MEK inhibition with one of the MEK inhibitors (shown in red box), KRAS mutated (Red lines) and BRAF mutated (Green lines) CRCs activate parallel pathways that incur resistance to MEK inhibition. Dual targeted inhibition of MEK with mTOR (shown in blue box), PI3K (shown in green box), AKT (shown in yellow box), IGF-1R (shown in purple box) or PI3K/mTOR (shown in orange) inhibitors has been studied to overcome this resistance. Regular arrow: activates; Arrow ending with a straight line: inhibits.
Figure 1 Cross talk between MAPK, PI3K and Wnt pathway in CRC. Upon MEK inhibition with one of the MEK inhibitors (shown in red box), KRAS mutated (Red lines) and BRAF mutated (Green lines) CRCs activate parallel pathways that incur resistance to MEK inhibition. Dual targeted inhibition of MEK with mTOR (shown in blue box), PI3K (shown in green box), AKT (shown in yellow box), IGF-1R (shown in purple box) or PI3K/mTOR (shown in orange) inhibitors has been studied to overcome this resistance. Regular arrow: activates; Arrow ending with a straight line: inhibits.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 127

Metadata

Authors
Temraz, S., Mukherji, D., & Shamseddine, A.
Affiliations
American University of Beirut Medical Center (LB)
Corresponding author
Temraz, Sally
Venue
International Journal of Molecular Sciences
Publisher
MDPI AG
Published
2015-09-23
Volume
16
Issue
9
Pages
22976-22988
ISSN
1422-0067 (ISSN-L)
OpenAlex
W2120687938
Cited by
117
References
55
Citations by year
2026: 4 · 2025: 8 · 2024: 12 · 2023: 9 · 2022: 2 · 2021: 9 · 2020: 13 · 2019: 15 · 2018: 19 · 2017: 16 · 2016: 10
FWCI
1.61
Type
journal article
Language
en
Open access
Locations
  • International Journal of Molecular Sciences (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
Keywords
colorectal cancer, MEK inhibitors, PI3K signaling, KRAS mutation, BRAF mutation, MAPK signaling, PI3K/mTOR inhibitors, drug resistance, Wnt signaling, PIK3CA, Akt, IGF-1 receptor, combination therapy
MeSH terms
Phosphoinositide-3 Kinase Inhibitors, Animals, Colon, Humans, Mutation, Rectum, Colorectal Neoplasms, Signal Transduction, Proto-Oncogene Proteins p21(ras), Mitogen-Activated Protein Kinase Kinases, Protein Kinase Inhibitors, Proto-Oncogene Proteins B-raf, Phosphatidylinositol 3-Kinase, TOR Serine-Threonine Kinases, Molecular Targeted Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.